title: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.
abstract: OBJECTIVE
  The aim of this retrospective analysis was to determine the outcome of patients with follicular lymphoma who received myeloablative therapy supported by autologous bone marrow transplantation as consolidation of second or subsequent remission, with a minimum follow-up of 12 years.
  
  
  METHODS
  One hundred twenty-one adults received cyclophosphamide (CY) and total-body irradiation (TBI) supported by autologous bone marrow transplantation, with the marrow mononuclear cell fraction having been treated with monoclonal antibodies and complement. Data from St Bartholomew's Hospital and Dana-Farber Cancer Institute were combined for the purpose of this analysis because the patients were treated in an identical manner.
  
  
  RESULTS
  Fifty-seven patients are alive, 41 without progression between 9 and 19 years; 64 patients have died, 20 without progression. With a median follow-up of 13.5 years, 60 patients have developed recurrent lymphoma. There is an apparent plateau on the remission duration curve at 48% at 12 years. Survival of patients treated in second remission was significantly longer than the survival of patients treated later in the course of the illness. Both remission duration and overall survival were also significantly longer for patients treated in second remission compared with an age-matched, remission-matched group of patients treated at St Bartholomew's Hospital before the introduction of this treatment. However, use of CY+TBI was associated with a significant risk of secondary myelodysplasia and secondary acute myeloblastic leukemia, resulting in 15 patient deaths.
  
  
  CONCLUSIONS
  These mature data confirm that prolonged freedom from recurrence may be achieved with myeloablative therapy and that a plateau on the curve seems to emerge with long follow-up.
authors.affiliation: Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom. ama.rohatiner@cancer.org.uk
authors.forename: Ama Z S
authors.initials: AZ
authors.lastname: Rohatiner
authors.forename: Lee
authors.initials: L
authors.lastname: Nadler
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Davies
authors.forename: John
authors.initials: J
authors.lastname: Apostolidis
authors.forename: Donna
authors.initials: D
authors.lastname: Neuberg
authors.forename: Janet
authors.initials: J
authors.lastname: Matthews
authors.forename: John G
authors.initials: JG
authors.lastname: Gribben
authors.forename: Peter M
authors.initials: PM
authors.lastname: Mauch
authors.forename: T Andrew
authors.initials: TA
authors.lastname: Lister
authors.forename: Arnold S
authors.initials: AS
authors.lastname: Freedman
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide